Adesão à Terapia Hormonal Adjuvante com Tamoxifeno e Anastrozol utilizando ARMS-12 e MMAS-4

Botelho, Lorena Oliveira de; Sañudo, Adriana; Facina, Gil; Wagner, Gabriela Arantes.
Rev. Bras. Cancerol. (Online) ; 68(2)Abr.-Jun. 2022.
Artículo en Portugués | LILACS | ID: biblio-1373277

Documentos relacionados

  1. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.
  2. Switching of Hormone Therapies in Breast Cancer Women.
  3. The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer.
  4. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
  5. Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review.
  6. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study.
  7. Switching of hormone therapies in breast cancer women
  8. Palliative treatment of endometrial cancer: what is the role of anastrozole in elderly women?
  9. [A Case of De Novo Stage Ⅳ Breast Cancer Successfully Treated with Surgery and Multiple Endocrine Therapies Over a Long Period of Time].
  10. Anastrozole as a therapeutic option for gynecomastia in a person receiving antiretroviral therapy: Case report.